Sub-Study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133).
Phase of Trial: Phase III
Latest Information Update: 22 Dec 2009
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms PRESTO
- Sponsors Teva Neuroscience
- 27 Dec 2007 Status changed from in progress to completed according to ClinicalTrials.gov.
- 31 Dec 2005 New trial record.